Unveiling the potential of Urolithin A in Cancer Therapy: Mechanistic Insights to Future Perspectives of Nanomedicine
Nanotheranostics · 2025
DOI: 10.7150/ntno.110966 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Nanotheranostics, 2025. Verfasst von Vinita Karumuru und 4 weiteren Autor:innen. Beteiligte Einrichtung: Micronutrient Information Center, Linus Pauling Institute, Oregon State University, Corvallis, OR 97331, USA. Hauptthemen laut MEDLINE: Coumarins, Neoplasms, Nanomedicine, Antineoplastic Agents. Die Arbeit wurde bisher 14-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS, NIMHD NIH HHS.
Abstract (Originalsprache)
Cancer remains a leading global health challenge, with high mortality rates persisting despite significant advancements in therapeutic interventions. Major obstacles, including systemic toxicity, therapy resistance, metastasis, and relapses, emphasize the urgent need for safer, more effective, and readily accessible treatment strategies. Among emerging alternatives, natural bioactive compounds have gained considerable attention because of their diverse therapeutic potential and lower toxicity profiles. Urolithin A (UA), a metabolite derived from ellagic acid through gut microbiota metabolism, has emerged as a compelling anticancer agent. UA has multiple mechanisms of action, including the regulation of autophagy, enhancement of mitochondrial function, and inhibition of tumor progression and metastatic pathways. Additionally, its chemo-, immuno-, and radio-sensitization properties further increase its therapeutic advantages. Nanotechnology-driven approaches, such as nanoparticle formulations, lipids, and powder formulations, have successfully increased the solubility, stability, bioavailability, precise targeted delivery to cancer tissues, and overall therapeutic benefits of these materials. This review comprehensively explores the anticancer mechanisms of UA, its modulatory role, and advances in nanoformulation strategies, highlighting its potential as a next-generation therapeutic agent for improved cancer treatment and prevention.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Micronutrient Information Center, Linus Pauling Institute, Oregon State University, Corvallis, OR 97331, USA.
- Division of Cancer Immunology and Microbiology, Medicine and Oncology Integrated Service Unit, School of Medicine, University of Texas Rio Grande Valley, McAllen, TX 78504, USA.
- South Texas Center of Excellence in Cancer Research, School of Medicine, University of Texas Rio Grande Valley, McAllen, TX 78504, USA.
- Wisconsin Center for NanoBioSystems, School of Pharmacy, University of Wisconsin, Madison, WI, USA.
Förderung
- NIGMS NIH HHS
- NIMHD NIH HHS
Zitieren
APA
Karumuru, V., Dhasmana, A., Mamidi, N., Chauhan, S. C., & Yallapu, M. M. (2025). Unveiling the potential of Urolithin A in Cancer Therapy: Mechanistic Insights to Future Perspectives of Nanomedicine. Nanotheranostics. https://doi.org/10.7150/ntno.110966
Vancouver
Karumuru V, Dhasmana A, Mamidi N, Chauhan SC, Yallapu MM. Unveiling the potential of Urolithin A in Cancer Therapy: Mechanistic Insights to Future Perspectives of Nanomedicine. Nanotheranostics. 2025. doi:10.7150/ntno.110966
BibTeX
@article{Karumuru2025,
author = {Karumuru, Vinita and Dhasmana, Anupam and Mamidi, Narsimha and Chauhan, Subhash C and Yallapu, Murali M},
title = {Unveiling the potential of Urolithin A in Cancer Therapy: Mechanistic Insights to Future Perspectives of Nanomedicine},
journal = {Nanotheranostics},
year = {2025},
doi = {10.7150/ntno.110966}
}
EUVIMED